Abcam, ab255784, Anti-EBNA2 antibody [R3] - BSA and Azide free

Size: 100µg / 1mg
Rat Recombinant Monoclonal EBNA2 antibody. Carrier free. Suitable for IP, WB and reacts with Human samples.
Key facts
Host species:Rat,
Clonality:Monoclonal,
Clone number:R3,
Isotype:IgG2a,
Carrier free:Yes,
Reacts with:Human,
Applications:WB, IPSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab255784 is the carrier-free version of
ab252828
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
EBNA2 also known as the Epstein-Barr virus nuclear antigen 2 (EBNA-2) plays a critical role in viral protein function. It is a transcriptional activator essential for the latent infection cycle of Epstein-Barr virus (EBV). EBNA2 binds to specific DNA sequences and interacts with other host cellular factors to initiate transcription. The molecular mass of EBNA2 typically is approximately 88 kDa. EBNA2 mainly expresses in EBV-infected B lymphocytes where it contributes to their immortalization and proliferation.
Biological function summary
EBNA2 is pivotal in the activation of several viral and cellular genes. It forms complexes with other proteins including the cellular transcription factor RBP-Jκ part of the Notch signaling pathway. This interaction is important for altering the expression patterns of both host and viral genes causing changes in the cell cycle and promoting latency. EBNA2 also regulates genes involved in immune response modulation aiding in viral persistence within the host by evading immune surveillance.
Pathways
EBNA2 impacts transcriptional regulation and cell signaling reversibly. It is integral to the Notch signaling and transcriptional activation pathway related to EBV latency. EBNA2 recruits proteins like CBF1 (RBP-Jκ) a transcription factor that helps mediate cell fate decisions and maintain latency. It modulates pathways involving c-MYC a central regulator of cell growth and influences transcriptional activity with a downstream effect on cellular transformation and proliferation.
EBNA2 is prominently associated with EBV-related malignancies such as Burkitt's lymphoma and Hodgkin's lymphoma. These cancers arise partly from the dysregulated cellular growth induced by EBNA2-mediated transcriptional changes. In these disorders EBNA2 may interact with proteins like LMP1 another EBV-encoded protein that aids in the transformation process promoting oncogenesis and affecting therapy resistance mechanisms.